China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...
Grand Pharmaceutical
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...
Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres...